Answers are grounded in this paper and cite their sources.
Adenosine A(1) receptors (A(1)R) are able to form a heteromeric complex with P2Y(1) receptors (P2Y(1)R) that generates A(1)R with P2Y(1)R-like agonistic pharmacology. A potent P2Y(1)R agonist, adenosine 5'-O-(2-thiotriphosphate), binds the A(1)R binding pocket of the A(1)R/P2Y(1)R complex and inhibits adenylyl cyclase activity via G(i/o) protein. These mechanisms might be used to fine-tune purinergic inhibition locally at sites where there is a particular oligomerization structure between purinergic receptors and explain the undefined purinergic functions by adenosine and adenine nucleotides.
No takes yet. Share an insight, caveat, or question.
Yoshioka et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: